San Diego, CA -- (SBWIRE) -- 04/10/2017 -- Corbus Pharmaceuticals Holdings is under investigation over potential securities laws violation. The investigation was announced for investors who purchased NASDAQ:CRBP shares.

Investors who purchased shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Corbus Pharmaceuticals Holdings Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Norwood, MA based Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company that is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. On March 30, 2017 Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum (fka JBT-101 or Resunab) compared to placebo for the treatment of patients with cystic fibrosis ("CF"). Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) declined from $10.35 per share on March 20, 2017 to as low as $7.00 per share on April 7, 2017.

Those who purchased shares of Corbus Pharmaceuticals Holdings Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com